Patent intelligence · US
US 6926909
Chrono delivery formulations and method of use thereof
Chrono delivery formulations and method of use thereof
Patent details — US 6926909
- Jurisdiction
- US
- Status
- expired
- Grant date
- Aug 9, 2005
- Expiration
- Aug 4, 2025
- Applicant
- Elite Laboratories, Inc.
- Claims
- 21
- CPC classes
- A61K, A61K31/554, A61K9/2081, A61K9/5026
Quick answer
US 6926909 (Chrono delivery formulations and method of use thereof) is held by Elite Laboratories, Inc.. Status: expired. Granted Aug 9, 2005. Expires Aug 4, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Elite Laboratories, Inc.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/554, A61K9/2081, A61K9/5026, A61K9/5078, A61P
More from Elite Laboratories, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12364693
Methods of treating metabolic diseases with fused bicyclic pyrazoles
granted -
US 12295394
Water-soluble additive composition
granted -
US 12116596
Method and apparatus for improved mesenchymal stem cell harvesting
granted -
US 12016853
Methods of treating RBP4 related diseases with triazolopyridines
granted -
US 11951100
Formulations of RBP4 inhibitors and methods of use
granted -
US 11723873
Oral dosage form of ticagrelor and preparation method thereof
granted -
US 11684596
Antidiabetic pharmaceutical compositions and preparation method thereof
granted -
US 11655454
Method and apparatus for improved mesenchymal stem cell harvesting
granted
Frequently asked questions
What is US patent 6926909?
US 6926909 (Chrono delivery formulations and method of use thereof) is held by Elite Laboratories, Inc.. Status: expired. Granted Aug 9, 2005. Expires Aug 4, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6926909?
Elite Laboratories, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.
When does US 6926909 expire?
Our index shows an expiration date of Aug 4, 2025 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.